GlassScriptPhysician profile
Susan Manzi
NPI 1538133285
$67,192.89
in general payments reported to CMS, 2019-2025
12 companies · $19K in 2025
The $19K reported for 2025 was more than what 92% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,622 · 2020: $22K · 2021: $14K · 2022: $2,191 · 2023: $5,251 · 2024: $455 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Honoraria: $2,460 · Travel and Lodging: $1,634 · Food and Beverage: $1,331 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,129.50 |
| Honoraria | $2,460.00 |
| Travel and Lodging | $1,634.30 |
| Food and Beverage | $1,331.04 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $45,705.75 | 2020-2025 | Saphnelo |
| Astrazeneca Uk Limited | $5,101.50 | 2022-2025 | |
| Lilly USA, LLC | $4,951.66 | 2019-2025 | Taltz |
| Ucb, INC. | $3,875.00 | 2019-2023 | |
| Glaxosmithkline, LLC. | $3,823.47 | 2019-2025 | Benlysta, Nucala |
| Autolus INC | $3,319.36 | 2025 | |
| Abbvie INC. | $150.32 | 2019-2024 | |
| Phadia US INC. | $101.60 | 2019 | |
| Janssen Biotech, INC. | $75.00 | 2025 | Tremfya |
| Aurinia Pharma U.S., INC. | $54.23 | 2022-2024 | Lupkynis |
| Axsome Therapeutics, INC. | $35.00 | 2025 | Auvelity |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Manzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.